Market Place
Sourcing Support
Avalyn Appoints Heather Turner as Chair of Board of Directors
14 Nov 2024 //
GLOBENEWSWIRE
Avalyn to Participate in Multiple Upcoming Investor Conferences
04 Nov 2024 //
GLOBENEWSWIRE
Avalyn CEO Lyn Baranowski Named a PharmaVoice 100 Honoree
08 Oct 2024 //
GLOBENEWSWIRE
Avalyn Presents Inhaled Pirfenidone At Lung Fibrosis Colloquium
30 Sep 2024 //
GLOBENEWSWIRE
Avalyn Presents AP01 Data For Pulmonary Fibrosis At ERS 2024
08 Sep 2024 //
GLOBENEWSWIRE
Avalyn Begins Global Phase 2b MIST Study for AP01 in Pulmonary Fibrosis
03 Sep 2024 //
GLOBENEWSWIRE
Avalyn to Participate in Multiple Upcoming Investor Conferences
29 Aug 2024 //
GLOBENEWSWIRE
Avalyn to Present Data for Pulmonary Fibrosis at European Respiratory Congress
26 Aug 2024 //
GLOBENEWSWIRE
Avalyn Announces Presentations On AP01 For Pulmonary Fibrosis At ERS Congress
26 Aug 2024 //
GLOBENEWSWIRE
Avalyn Initiates Phase 1b Study For Inhaled Nintedanib AP02
12 Aug 2024 //
GLOBENEWSWIRE
Avalyn Appoints Erin Lavelle To Board Of Directors
05 Aug 2024 //
GLOBENEWSWIRE
Avalyn to Participate in Multiple Upcoming Investor Conferences
01 Aug 2024 //
GLOBENEWSWIRE
Avalyn to Participate in Jefferies Global Healthcare Conference
28 May 2024 //
GLOBENEWSWIRE
Avalyn Presents AP01 Long-Term, Imaging Data In Pulmonary Fibrosis
20 May 2024 //
GLOBENEWSWIRE
Avalyn Presents On AP01, Novel Inhaled Therapies At ATS 2024
13 May 2024 //
GLOBENEWSWIRE
Avalyn Appoints Douglas Carlson As CFO & CBO
01 May 2024 //
GLOBENEWSWIRE
Avalyn to Participate in Leerink Partners Global Biopharma Conference
06 Mar 2024 //
GLOBENEWSWIRE
Avalyn to Participate in Multiple Upcoming Investor Conferences
06 Feb 2024 //
GLOBENEWSWIRE
Avalyn to Participate in the 2023 RBC Capital Markets Healthcare Conference
06 Dec 2023 //
GLOBENEWSWIRE
Avalyn Presents Data from its AP01 and AP02 Inhaled Therapeutics Programs
09 Nov 2023 //
GLOBENEWSWIRE
Avalyn Strengthens Leadership Team with Key Appointments
06 Nov 2023 //
GLOBENEWSWIRE
Avalyn to Participate in Multiple Upcoming Investor Conferences
05 Oct 2023 //
GLOBENEWSWIRE
Avalyn to Provide Keynote Presentation at U.S. 2023 Conference
29 Sep 2023 //
GLOBENEWSWIRE
Avalyn Raises $175 Million in Oversubscribed Series C Financing
27 Sep 2023 //
GLOBENEWSWIRE
Avalyn raises $175M to test inhaler versions of IPF medicines in PhII trials
27 Sep 2023 //
ENDPTS
Avalyn Pharma`s CEO Leads Workshop on Clinical Strategy at IPF Summit
18 Sep 2023 //
GLOBENEWSWIRE
Avalyn Pharma Presents Data Showing Favorable Tolerability and Potential of AP01
12 Sep 2023 //
GLOBENEWSWIRE
Avalyn Pharma Appoints Melissa Rhodes, to the Role of Chief Operating Officer
11 Sep 2023 //
GLOBENEWSWIRE
Avalyn Pharma`s Inhaled Pulmonary Fibrosis Programs to be Highlighted
07 Sep 2023 //
GLOBENEWSWIRE
Avalyn Pharma Appointed Howard M. Lazarus, MD, FCCP to the Role of CMO
07 Aug 2023 //
GLOBENEWSWIRE
Avalyn Pharma Invited to Present at Canaccord Genuity Annual Growth Conference
27 Jul 2023 //
GLOBENEWSWIRE
Avalyn Pharma Highlighting Inhalation Platform at Upcog H.C. Wainwright
15 Jun 2023 //
GLOBENEWSWIRE
Avalyn Pharma Made Corporate and Clinical Presentations at ATS 2023
23 May 2023 //
GLOBENEWSWIRE
Avalyn Showcasing Therapeutic Approach and Clinical Status at ATS 2023
11 May 2023 //
GLOBENEWSWIRE
Avalyn Reports Data After 1 Year of Treatment in AP01 Open-label Extension Trial
11 Apr 2023 //
GLOBENEWSWIRE
Avalyn Pharma Reports Results of Phase 1 Study of AP02
30 Mar 2023 //
GLOBENEWSWIRE
Avalyn Pharma Publishes Ph1b ATLAS Results Stabilization of Lung Function
23 Mar 2023 //
GLOBENEWSWIRE
Avalyn Pharma Invited to Participate in the Annual ISI HealthCONx Conference
28 Nov 2022 //
GLOBENEWSWIRE
Avalyn Pharma Appoints Lyn Baranowski Chief Executive Officer
17 Oct 2022 //
BUSINESSWIRE
Avalyn Pharma Appoints Lyn Baranowski CEO
17 Oct 2022 //
CONTRACTPHARMA
Marc Schneebaum Joins Avalyn Pharma as CFO
20 Oct 2021 //
BUSINESSWIRE
Avalyn Pharma Reports Statistically Significant Dose Response with Aerosolized
24 May 2021 //
BUSINESSWIRE
Avalyn Pharma Reports Update in Ongoing Idiopathic Pulmonary Fibrosis Trial
16 Oct 2020 //
BUSINESSWIRE
Avalyn Pharma Reports Update in Ongoing Idiopathic Pulmonary Fibrosis Trial
16 Oct 2020 //
BUSINESSWIRE
